Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018

Francisco, CA-based Vaxart, which is developing an oral flu vaccine.

However, neither Vaxart nor any other business that Radspinner knows of uses the same technology as RedeeFlu. The vaccine is made up of a replicating live flu virus from which a key gene has been deleted. The vaccine virus is able to live in the body just long enough to provoke a strong immune response, but thanks to the deleted gene it’s not able to cause disease or spread to other people.

“The live virus, single-replication—we’re the only one in the game there,” Radspinner says.

Author: Jeff Buchanan

Jeff formerly led Xconomy’s Seattle coverage since. Before that, he spent three years as editor of Xconomy Wisconsin, primarily covering software and biotech companies based in the Badger State. A graduate of Vanderbilt, he worked in health IT prior to being bit by the journalism bug.